GlassScriptPhysician profile
Rajendra Patel
NPI 1316940836
$3,937.97
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,127 · 2020: $908 · 2021: $538 · 2022: $872 · 2023: $352 · 2024: $141.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $473 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $473.44 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,077.47 | 2019-2023 | Farxiga, Breztri |
| Novo Nordisk INC | $714.11 | 2019-2024 | Ozempic, Rybelsus |
| Pfizer INC. | $427.53 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $403.40 | 2019-2023 | |
| Glaxosmithkline, LLC. | $364.79 | 2019-2023 | Trelegy Ellipta |
| Lilly USA, LLC | $257.01 | 2019-2024 | Mounjaro, Zepbound |
| Takeda Pharmaceuticals U.S.A., INC. | $176.61 | 2020-2022 | |
| Allergan, INC. | $153.72 | 2019-2020 | |
| Abbvie INC. | $67.49 | 2021-2022 | |
| Amgen INC. | $51.65 | 2020-2021 | |
| Ibsa Pharma INC. | $38.96 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $35.58 | 2023 | |
| Dexcom, INC. | $29.53 | 2024 | Dexcom G6 Transmitter |
| Viiv Healthcare Company | $27.57 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $20.79 | 2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.57 | 2022 | |
| Optos, INC. | $19.53 | 2020 | |
| Kyowa Kirin, INC. | $18.12 | 2024 | Crysvita |
| Eisai INC. | $15.08 | 2021 | |
| Endo Pharmaceuticals INC. | $10.99 | 2020 | |
| Linus Health, INC. | $8.47 | 2024 | Core Cognitive Evaluation |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajendra Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.